Search clinical trials for: ProNOVA XR Polymer Free Drug Eluting Coronary Stent System

Total 361127 results

Fondazione Ricerca e Innovazione Cardiovascolare...

Recruiting

Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels (TRANSFORM II)

Coronary Artery Disease | Coronary Artery Stenosis

Spain, Netherlands, Italy, France, Bangladesh
Amsterdam UMC, location VUmc

Recruiting

Drug-Coated Balloon Coronary Angioplasty Versus Stenting for Treatment of Disease Adjacent to a Chronic Total Occlusion. (Co-CTO)

Chronic Total Occlusion of Coronary Artery

Netherlands
Semmelweis University Heart and Vascular Center

Recruiting

Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis (OPEN-ISR)

Coronary Stent Restenosis

Hungary
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
Peking University Third Hospital

Not yet recruiting

Comparative Clinical Study of Drug-coating Balloon Strategy and Drug-eluting Stent Strategy (Kissing-DCB)

Coronary Artery Disease

China
North Karelia Central Hospital
Turku University Hospital; Helsinki University Central Hospital; Oulu University... and other collaborators

Recruiting

Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI (DEBATE)

Coronary Artery Disease

Finland, France, Germany, United Kingdom
Biotronik AG

Recruiting

Resorbable Magnesium Scaffolds Registry

Coronary Artery Disease

Germany
Liu Bin

Not yet recruiting

Drug-coated Balloon Versus Drug-eluting Stent for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography

Coronary Artery Disease | Angioplasty

China
University Hospital Ulm

Recruiting

Coronary Interventions Ulm - Coronary Chronic Total Occlusions (CSI)

Chronic Total Occlusion | Chronic Total Occlusion of Coronary Artery

Germany
Merck Sharp & Dohme LLC

Recruiting

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Small Cell Lung Cancer

United States, Australia, Belgium, Bulgaria, Canada, China, France, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Portugal, Romania, Russian Federation, Serbia, South Africa, Spain, Turkey, Ukraine, United... and more
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Shanghai Zhongshan Hospital

Not yet recruiting

A Comparison Between FFR Guided and CAG Guided Treatment Using DEB in ISR of DES

Coronary Artery Disease | In Stent Restenosis | Drug Eluting Stent
Norfolk and Norwich University Hospitals NHS Foundation...
University of East Anglia

Recruiting

Drug Coated Balloon Only vs Drug Eluting Stent Angioplasty

Coronary Artery Disease

United Kingdom
Collegium Medicum w Bydgoszczy

Recruiting

ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction (ANEMON)

ST Elevation Myocardial Infarction | Non ST Segment Elevation Acute Coronary Syndrome

Poland
St. Antonius Hospital
Daiichi Sankyo, Inc.

Recruiting

What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? (WOEST-3)

Myocardial Infarction | Coronary Artery Disease | Stroke | Embolism | Atrial Fibrillation | Bleeding | Acute Coronary Syndrome | Atrial Flutter | NSTEMI - Non-ST Segment Elevation MI | Stent Thrombosis | STEMI - ST Elevation Myocardial Infarction

Belgium, Netherlands
Duk-Woo Park, MD

Recruiting

Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy (PROTECT-HBR)

Myocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | Percutaneous Coronary Intervention

Korea, Republic of
Clinical Hospital Center Rijeka

Not yet recruiting

Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID (PRO-DAVID)

Coronary Artery Disease | Ischemic Heart Disease | Stable Angina | Unstable Angina | NSTEMI - Non-ST Segment Elevation MI
Ministry of Health, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo; InCor Heart Institute

Recruiting

Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms (ARAMIS)

Refractory Angina

Brazil
Yonsei University

Recruiting

Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

Atrial Fibrillation

Korea, Republic of
Yonsei University

Not yet recruiting

Determination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents

Coronary Artery Disease

Korea, Republic of
University of Leicester
University of Tromso; KU Leuven; Ludwig-Maximilians - University of Munich; University... and other collaborators

Recruiting

Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock (EUROSHOCK)

Cardiogenic Shock

Spain, Germany, Belgium, United Kingdom, Austria, Italy, Latvia, Norway
Yonsei University

Recruiting

Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial

Coronary Artery Disease, Acute Coronary Syndrome

Korea, Republic of
Merck Sharp & Dohme LLC
AstraZeneca

Recruiting

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Advanced Solid Neoplasms

United States, Argentina, Australia, Canada, Colombia, Denmark, France, Guatemala, Ireland, Israel, Japan, Korea, Republic of, Mexico, Peru, Romania, Russian Federation, Spain, Turkey, United Kingdom, Switzerland, Italy
Fundación EPIC

Recruiting

Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) (RETO 320)

Coronary Artery Disease

Spain
JW Medical Systems Ltd

Not yet recruiting

A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT

Coronary Artery Disease

China
Lifetech Scientific (Shenzhen) Co., Ltd.

Recruiting

A First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System

Single Coronary Vessel Disease

Malaysia
Shanghai MicroPort Medical (Group) Co., Ltd.

Recruiting

Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease

Coronary Disease | Percutaneous Coronary Intervention | Dual Antiplatelet Therapy | Drug Eluting Stent

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)

Non-valvular Atrial Fibrillation (NVAF) | Acute Coronary Syndrome (ACS)

China
Seung-Jung Park
CardioVascular Research Foundation, Korea

Recruiting

IRIS-BioFreedom Cohort in the IRIS-DES Registry (IRISBioFreedom)

Coronary Stenosis

Korea, Republic of
VA Office of Research and Development

Recruiting

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)

Atherosclerosis | Prediabetic State | Metformin

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
Seung-Jung Park
CardioVascular Research Foundation, Korea; Medtronic Korea Co., Ltd.

Recruiting

IRIS-Onyx Cohort in the IRIS-DES Registry (IRIS-Onyx)

Cardiovascular Diseases | Coronary Artery Disease | Arterial Occlusive Diseases | Percutaneous Transluminal Angioplasty

Korea, Republic of
Yonsei University

Recruiting

Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

Acute Coronary Syndrome

Korea, Republic of
Seung-Jung Park

Recruiting

Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)

Coronary Artery Disease

Korea, Republic of
Seung-Jung Park
CardioVascular Research Foundation, Korea

Recruiting

Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice (IRIS-DES)

Coronary Artery Disease | Percutaneous Transluminal Coronary Angioplasty

Korea, Republic of
Biotronik AG
Biotronik France

Active, not recruiting

BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry (BIOFLOW-VIII)

Myocardial Ischemia | Coronary Artery Disease

France
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Hoffmann-La Roche
Foundation Medicine, Inc.

Active, not recruiting

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)

Cancer of Unknown Primary Site

United Kingdom, Korea, Republic of, France, Australia, Germany, Austria, Croatia, Denmark, Finland, Greece, Hungary, Italy, Portugal, Spain, Japan, Brazil, Colombia, Mexico, Romania, Czechia, Norway, Thailand, Switzerland, Turkey, Nethe... and more
Kyoto University, Graduate School of Medicine

Active, not recruiting

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study (STOPDAPT-3)

Acute Coronary Syndrome

Japan
Boston Scientific Corporation

Completed

The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia (SAVAL)

Critical Limb Ischemia

United States, France, Japan, Belgium, Netherlands
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Extensive Stage Lung Small Cell Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States, Guam
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7 | Metastatic Breast Carcinoma | Metastatic BRCA Hereditary Breast Carcinoma

United States, Puerto Rico
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States

Search clinical trials for: ProNOVA XR Polymer Free Drug Eluting Coronary Stent System

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations